1. Home
  2. TR vs IMNM Comparison

TR vs IMNM Comparison

Compare TR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tootsie Roll Industries Inc.

TR

Tootsie Roll Industries Inc.

HOLD

Current Price

$38.39

Market Cap

3.2B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.58

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TR
IMNM
Founded
1896
2006
Country
United States
United States
Employees
2100
N/A
Industry
Specialty Foods
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TR
IMNM
Price
$38.39
$18.58
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$32.80
AVG Volume (30 Days)
143.2K
1.1M
Earning Date
04-23-2026
05-08-2026
Dividend Yield
0.85%
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$32.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.70
$7.96
52 Week High
$45.06
$27.65

Technical Indicators

Market Signals
Indicator
TR
IMNM
Relative Strength Index (RSI) 43.28 34.55
Support Level $36.86 $16.81
Resistance Level $43.20 $19.16
Average True Range (ATR) 1.16 1.23
MACD -0.05 -0.30
Stochastic Oscillator 37.85 0.43

Price Performance

Historical Comparison
TR
IMNM

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: